ProBioGen AG vs Viralgen

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/probiogen/viralgen

Category	ProBioGen AG	Viralgen
Listed site	cdmo	cdmo
Summary	ProBioGen AG is a CDMO offering cell line development, process development, GMP manufacturing and analytical services for proteins, antibodies, viral vectors and vaccines. It also provides technology platforms for biopharmaceutical manufacturing.	Viralgen is a CDMO specializing exclusively in cGMP AAV gene therapy manufacturing, with the world's largest dedicated AAV production capacity and a 100% success rate for IND/IMPD dossiers across 50+ gene therapy customers.
Services	Analytical Method Development & Validation ICH Stability Studies EU EMA Regulatory Strategy US FDA Regulatory Strategy Cell-Line Development Process Development Biologics Development & Manufacturing Recombinant Protein Manufacturing Monoclonal Antibody (mAb) Manufacturing Viral Vector Manufacturing AAV Manufacturing Lentiviral Vector Manufacturing Vaccine Manufacturing Technology Transfer CMC Analytical Development Quality Control Testing Stability Testing & Storage Formulation Development CMC Regulatory Submission Support	Analytical Method Development & Validation Regulatory Affairs EU EMA Regulatory Strategy US FDA Regulatory Strategy
Modalities	Biologics (Monoclonal Antibodies) Biologics (Other) Gene Therapy Vaccine AAV / Viral Vector Platform	AAV / Viral Vector Platform Gene Therapy
Indications	Oncology	Rare Disease
Locations	Berlin, Berlin, Berlin, Germany Cairo, Cairo, Cairo Governorate, Egypt Headquarters, Berlin, Berlin, Germany Office, Berlin, Berlin, Germany	Headquarters & Manufacturing, San Sebastián, Basque Country, Spain
Certifications	EMA · Identifier: GMP compliant FDA · Identifier: GMP compliant	EMA · Identifier: AEMPS/EMA certified
Reviews	Review summary appears after site-level review signal gate opens.	Review summary appears after site-level review signal gate opens.